XML 122 R107.htm IDEA: XBRL DOCUMENT v3.23.1
Supplemental Financial Information - Cash Flows (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Cash flows from operating activities      
Net income $ 125.3 $ 594.8  
Adjustments to reconcile net income to net cash flows from operating activities:      
Depreciation and amortization 44.0 19.4  
Equity-based compensation 54.4 39.7  
Non-cash performance allocations and incentive fees, net (36.7) (300.8)  
Non-cash principal investment income (7.7) (315.3)  
Other non-cash amounts 10.8 5.3  
Purchases of investments (18.5) (307.5)  
Proceeds from the sale of investments 78.6 158.3  
Payments of contingent consideration (68.6) (5.7)  
Changes in deferred taxes, net (15.1) 110.9  
Change in due from affiliates and other receivables 16.9 (9.5)  
Change in deposits and other (33.9) (39.8)  
Change in accounts payable, accrued expenses and other liabilities (63.9) (14.3)  
Change in accrued compensation and benefits (371.9) (580.1)  
Change in due to affiliates (0.2) (0.2)  
Change in lease right-of-use assets and lease liabilities (2.8) (2.5)  
Change in deferred revenue 284.7 254.5  
Net cash used in operating activities (112.5) (371.7)  
Cash flows from investing activities      
Purchases of corporate treasury investments (101.1) 0.0  
Proceeds from corporate treasury investments 20.1 0.0  
Purchases of fixed assets, net (12.9) (12.3)  
Purchase of CBAM intangibles and investments, net 0.0 (618.4)  
Net cash used in investing activities (93.9) (630.7)  
Cash flows from financing activities      
Payments on CLO borrowings (1.1) (8.9)  
Proceeds from CLO borrowings, net of financing costs 0.0 40.8  
Dividends to common stockholders (118.4) (89.5)  
Payment of deferred consideration for Carlyle Holdings units (68.8) (68.8)  
Contributions from non-controlling interest holders 18.7 146.8  
Distributions to non-controlling interest holders (9.9) (147.1)  
Common shares issued for performance allocations 0.0 31.3  
Common shares repurchased (100.3) (80.4)  
Change in due to/from affiliates financing activities 74.6 33.1  
Net cash used in financing activities (136.5) (164.5)  
Effect of foreign exchange rate changes 8.3 (17.4)  
Decrease in cash, cash equivalents and restricted cash (334.6) (1,184.3)  
Cash, cash equivalents and restricted cash, beginning of period 1,361.5 2,475.1  
Cash, cash equivalents and restricted cash, end of period 1,026.9 1,290.8  
Reconciliation of cash, cash equivalents and restricted cash, end of period:      
Cash and cash equivalents 1,010.1 1,290.2 $ 1,360.7
Restricted cash 16.8 0.6 0.8
Total cash, cash equivalents and restricted cash, end of period 1,026.9 1,290.8 1,361.5
Cash and cash equivalents held at Consolidated Funds 228.8 168.9 209.0
Consolidated Operating Entities      
Cash flows from operating activities      
Net income 108.1 569.7  
Adjustments to reconcile net income to net cash flows from operating activities:      
Depreciation and amortization 44.0 19.4  
Equity-based compensation 54.4 39.7  
Non-cash performance allocations and incentive fees, net (38.2) (300.8)  
Non-cash principal investment income (8.7) (295.4)  
Other non-cash amounts 10.8 5.3  
Purchases of investments (19.0) (294.1)  
Proceeds from the sale of investments 78.9 169.5  
Payments of contingent consideration (68.6) (5.7)  
Changes in deferred taxes, net (15.1) 110.9  
Change in due from affiliates and other receivables 17.0 (8.8)  
Change in deposits and other (33.9) (39.8)  
Change in accounts payable, accrued expenses and other liabilities (63.9) (14.3)  
Change in accrued compensation and benefits (371.9) (580.1)  
Change in due to affiliates (0.2) (0.2)  
Change in lease right-of-use assets and lease liabilities (2.8) (2.5)  
Change in deferred revenue 284.7 254.5  
Net cash used in operating activities (24.4) (372.7)  
Cash flows from investing activities      
Purchases of corporate treasury investments (101.1) 0.0  
Purchases of fixed assets, net (12.9) (12.3)  
Purchase of CBAM intangibles and investments, net 0.0 (618.4)  
Net cash used in investing activities (93.9) (630.7)  
Cash flows from financing activities      
Payments on CLO borrowings (1.1) (8.9)  
Proceeds from CLO borrowings, net of financing costs 0.0 40.8  
Dividends to common stockholders (118.4) (89.5)  
Payment of deferred consideration for Carlyle Holdings units (68.8) (68.8)  
Contributions from non-controlling interest holders 2.0 5.8  
Distributions to non-controlling interest holders (8.5) (27.1)  
Common shares issued for performance allocations 0.0 31.3  
Common shares repurchased (100.3) (80.4)  
Change in due to/from affiliates financing activities 73.0 33.1  
Net cash used in financing activities (222.1) (163.7)  
Effect of foreign exchange rate changes 5.8 (17.2)  
Decrease in cash, cash equivalents and restricted cash (334.6) (1,184.3)  
Cash, cash equivalents and restricted cash, beginning of period 1,361.5 2,475.1  
Cash, cash equivalents and restricted cash, end of period 1,026.9 1,290.8  
Supplemental non-cash disclosures      
Issuance of common shares related to the acquisition of CBAM 0.0 194.5  
Reconciliation of cash, cash equivalents and restricted cash, end of period:      
Cash and cash equivalents 1,010.1 1,290.2  
Restricted cash 16.8 0.6  
Total cash, cash equivalents and restricted cash, end of period 1,026.9 1,290.8 $ 1,361.5
Cash and cash equivalents held at Consolidated Funds 228.8 168.9  
Consolidated Operating Entities | MRE      
Cash flows from investing activities      
Proceeds from corporate treasury investments $ 20.1 $ 0.0